Amgen Faces Patent Cliff and Biosimilar Competition Impacting Growth Outlook
PILLAR DIAGNOSTIC // WEEK 02
“A looming patent cliff and intensifying biosimilar competition are set to cap Amgen’s near-term growth, a risk markets have yet to fully acknowledge; with the tape only mildly retracing, expect a gradual repricing lower once updated guidance underscores margin pressure.”
Proposed action
Trim exposure or avoid chasing further upside
THE MECHANICS
Tape & flow
Shares pulled back modestly around $327.64 after rising 11.4% over the past 90 days.
THE MACHINE
Operational momentum
Quarterly revenue is expected to rise about 4.2% to $9.47 billion while EPS declines roughly 10.7% to $4.74; full-year EPS consensus anticipates 7.3% growth to $21.28. Long-term targets envision about $37.4 billion in revenue and $8.2 billion in earnings by 2028. Recent acquisitions totaling approximately $840 million and FDA approval of Uplizna expand the pipeline, and late-stage assets like MariTide and olpasiran are positioned to drive growth through 2030.
THE MAP
Structure & constraints
Reliance on aging therapies, upcoming patent expiries and intensifying biosimilar competition alongside drug pricing reforms and potential government price controls threaten revenue and margins, even as pipeline expansions and acquisitions seek to bolster future growth.
THE MOOD
Consensus & positioning
Investors view Amgen as marginally undervalued against fair-value models, energized by dividend consistency, advancing pipeline candidates, and up-revised price targets, yet a subset is weighing if recent target breaches merit profit-taking.
